$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000139047815000037 Filed on August 06, 2015

Income Statement

Concept	2015 Q2	2014 Q4	2014 Q2
Revenue	$3.382M	$3.200M	$2.331M
YoY Change	45.09%	122.84%	-31.08%
Cost Of Revenue	$468.0K	$480.0K	$347.0K
YoY Change	34.87%	118.18%
Gross Profit	$2.914M	$2.720M	$1.984M
YoY Change	46.88%	121.32%	-31.91%
Gross Profit Margin	86.16%	85.0%	85.11%
Selling, General & Admin	$1.886M	$7.650M	$9.600M
YoY Change	-80.35%	22.79%	254.24%
% of Gross Profit	64.72%	281.25%	483.87%
Research & Development	$7.197M	$6.270M	$8.069M
YoY Change	-10.81%	-11.57%	52.94%
% of Gross Profit	246.98%	230.51%	406.7%
Depreciation & Amortization	$560.0K	$20.00K	$230.0K
YoY Change	143.48%	-83.33%	475.0%
% of Gross Profit	19.22%	0.74%	11.59%
Operating Expenses	$9.083M	$14.10M	$17.67M
YoY Change	-48.59%	4.83%	121.25%
Operating Profit	-$9.083M	-$11.38M	-$15.78M
YoY Change	-42.45%	-6.88%	97.63%
Interest Expense	-$4.490M	$3.200M	-$3.670M
YoY Change	22.34%	-109.23%	2723.08%
% of Operating Profit
Other Income/Expense, Net	$83.00K	$230.0K	-$19.94M
YoY Change	-100.42%	-160.53%	147.53%
Pretax Income	-$13.49M	-$7.960M	-$15.95M
YoY Change	-15.42%	-83.2%	97.99%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$15.66M	-$7.960M	-$19.94M
YoY Change	-21.47%	44.31%	-470.03%
Net Earnings / Revenue	-463.04%	-248.75%	-855.47%
Basic Earnings Per Share	-$0.10
Diluted Earnings Per Share	-$1.566B	-$1.921B	-$4.029B
COMMON SHARES
Basic Shares Outstanding	161.4M shares	121.5M shares	118.0M shares
Diluted Shares Outstanding	161.4M shares

Balance Sheet

Concept	2015 Q2	2014 Q4	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$45.30M	$23.70M	$39.20M
YoY Change	15.56%	-50.4%	46.79%
Cash & Equivalents	$45.28M	$23.65M	$39.16M
Short-Term Investments
Other Short-Term Assets	$2.600M	$28.40M	$1.900M
YoY Change	36.84%	1675.0%	280.0%
Inventory	$1.426M	$655.0K	$433.0K
Prepaid Expenses
Receivables	$1.818M	$1.839M	$2.152M
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$51.12M	$52.10M	$43.68M
YoY Change	17.03%	-24.26%	58.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$532.0K	$285.0K	$623.0K
YoY Change	-14.61%	-9.24%	33.4%
Goodwill	$6.069M	$5.897M	$5.898M
YoY Change	2.9%	-0.02%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.200M	$100.0K	$100.0K
YoY Change	8100.0%	0.0%	0.0%
Total Long-Term Assets	$50.85M	$28.39M	$36.59M
YoY Change	38.95%	47.92%	6.21%
TOTAL ASSETS
Total Short-Term Assets	$51.12M	$52.10M	$43.68M
Total Long-Term Assets	$50.85M	$28.39M	$36.59M
Total Assets	$102.0M	$80.49M	$80.28M
YoY Change	27.02%	-8.51%	29.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.318M	$1.886M	$2.036M
YoY Change	13.85%	-1.1%	-2.68%
Accrued Expenses	$12.92M	$8.885M	$11.79M
YoY Change	9.62%	83.54%	39.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.079M	$3.910M	$4.076M
YoY Change	0.07%	81.95%	1254.15%
Total Short-Term Liabilities	$38.11M	$27.23M	$33.41M
YoY Change	14.07%	-56.41%	29.75%
LONG-TERM LIABILITIES
Long-Term Debt	$2.546M	$4.492M	$6.003M
YoY Change	-57.59%	-41.99%	-36.16%
Other Long-Term Liabilities	$6.900M	$6.700M	$7.500M
YoY Change	-8.0%	-1.47%	15.38%
Total Long-Term Liabilities	$2.546M	$4.492M	$6.003M
YoY Change	-57.59%	-41.99%	-36.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.11M	$27.23M	$33.41M
Total Long-Term Liabilities	$2.546M	$4.492M	$6.003M
Total Liabilities	$52.60M	$43.43M	$51.97M
YoY Change	1.23%	-47.1%	11.11%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$294.9M	$256.4M	$233.5M
YoY Change	26.29%	35.94%	70.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M	$3.849M	$3.849M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	675.0K shares	675.0K shares	675.0K shares
Shareholders Equity	$49.37M	$37.06M	$28.31M
YoY Change
Total Liabilities & Shareholders Equity	$102.0M	$80.49M	$80.28M
YoY Change	27.02%	-8.51%	29.47%

Cashflow Statement

Concept	2015 Q2	2014 Q4	2014 Q2
OPERATING ACTIVITIES
Net Income	-$15.66M	-$7.960M	-$19.94M
YoY Change	-21.47%	44.31%	-470.03%
Depreciation, Depletion And Amortization	$560.0K	$20.00K	$230.0K
YoY Change	143.48%	-83.33%	475.0%
Cash From Operating Activities	-$11.86M	-$10.73M	-$12.97M
YoY Change	-8.56%	26.38%	82.16%
INVESTING ACTIVITIES
Capital Expenditures	$450.0K	-$110.0K	-$310.0K
YoY Change	-245.16%	-97.89%	-29.55%
Acquisitions
YoY Change
Other Investing Activities	-$500.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$50.00K	-$110.0K	-$310.0K
YoY Change	-83.87%	-96.07%	-338.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.330M	9.850M	20.00K
YoY Change	21550.0%	28.09%	-99.81%
NET CHANGE
Cash From Operating Activities	-11.86M	-10.73M	-12.97M
Cash From Investing Activities	-50.00K	-110.0K	-310.0K
Cash From Financing Activities	4.330M	9.850M	20.00K
Net Change In Cash	-7.580M	-990.0K	-13.26M
YoY Change	-42.84%	-72.5%	-485.47%
FREE CASH FLOW
Cash From Operating Activities	-$11.86M	-$10.73M	-$12.97M
Capital Expenditures	$450.0K	-$110.0K	-$310.0K
Free Cash Flow	-$12.31M	-$10.62M	-$12.66M
YoY Change	-2.76%	224.77%	89.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
	dei	Trading Symbol TradingSymbol	GALE
CY2014Q4	gale	Accrued Inventory Purchases Current AccruedInventoryPurchasesCurrent	0	USD
CY2015Q2	gale	Accrued Inventory Purchases Current AccruedInventoryPurchasesCurrent	420000	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	6439000	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-3115000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-656000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-238000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	161862321	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	490000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	656000	USD
CY2015Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-83000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	238000	USD
	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	3115000	USD
CY2013Q2	gale	Classof Warrantor Right Average Market Price Used For Exercise Price ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice	P20D
	gale	Classof Warrantor Right Expired ClassofWarrantorRightExpired	238000	shares
	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	14006000	shares
CY2013Q2	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P7Y
CY2015Q2	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	674000	shares
CY2014Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6651000	USD
CY2015Q2	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6889000	USD
CY2014Q4	gale	Contract Research Payable ContractResearchPayable	6967000	USD
CY2015Q2	gale	Contract Research Payable ContractResearchPayable	5779000	USD
CY2014Q3	gale	Contractual Obligation Potential Paymentsfrom Net Sales ContractualObligationPotentialPaymentsfromNetSales	16500000	USD
CY2014Q4	gale	Credit Memos Acquisition Channel Inventory Current CreditMemosAcquisitionChannelInventoryCurrent	1995000	USD
CY2015Q2	gale	Credit Memos Acquisition Channel Inventory Current CreditMemosAcquisitionChannelInventoryCurrent	1995000	USD
CY2013Q2	gale	Debt Instrument Cash Facility Fee DebtInstrumentCashFacilityFee	0.01
CY2013Q2	gale	Debt Instrument Cash Final Payment DebtInstrumentCashFinalPayment	0.055
CY2013Q2	gale	Debt Instrument Term Interest Only DebtInstrumentTermInterestOnly	P12M
CY2014Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-215481000	USD
CY2015Q2	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-241678000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	5582000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y6M15D
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	10296000	USD
CY2014Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	5383000	USD
CY2015Q2	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	18794000	USD
CY2014Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	5383000	USD
CY2015Q2	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	18794000	USD
	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	10296000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	1.93
CY2014Q4	gale	Future Milestone Payment FutureMilestonePayment	740000	USD
CY2015Q2	gale	Future Milestone Payment FutureMilestonePayment	240000	USD
CY2014Q4	gale	Gale401rights GALE401rights	9255000	USD
CY2015Q2	gale	Gale401rights GALE401rights	9255000	USD
CY2014Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2015Q2	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2015Q2	gale	Loss Contingency Percentageof Legal Fees Paid LossContingencyPercentageofLegalFeesPaid	0.88
CY2014Q2	gale	Loss On Warrant Exchange LossOnWarrantExchange	3353000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	-6439000	USD
CY2015Q2	gale	Loss On Warrant Exchange LossOnWarrantExchange	4267000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	3115000	USD
CY2014Q3	gale	Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents	P90D
CY2014Q2	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	-1000	USD
	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	0	USD
CY2015Q2	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	0	USD
	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	0	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	10585000	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	0	USD
CY2015Q2	gale	Numberof Commerical Products NumberofCommericalProducts	1	products
CY2013Q2	gale	Numberof Days Averagedfor Exercise Price NumberofDaysAveragedforExercisePrice	P20D
CY2015Q2	gale	Numberof Dosing Strengths NumberofDosingStrengths	6	dosing_strength
CY2015Q1	gale	Numberof Shares Per Unit NumberofSharesPerUnit	0.50	shares
CY2014Q2	gale	Numberof Top Performing Pharmacies NumberofTopPerformingPharmacies	3	pharmacy
	gale	Numberof Top Performing Pharmacies NumberofTopPerformingPharmacies	3	pharmacy
CY2015Q2	gale	Numberof Top Performing Pharmacies NumberofTopPerformingPharmacies	3	pharmacy
	gale	Numberof Top Performing Pharmacies NumberofTopPerformingPharmacies	3	pharmacy
CY2015Q2	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	10066000	shares
CY2014Q4	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	2444000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1839000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1818000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15669000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12923000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	860000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	1272000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1452000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3136000	USD
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1087000	USD
CY2014Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	408000	USD
CY2015Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	431000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	256377000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	294877000	USD
CY2015Q2	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	953000	USD
CY2015Q2	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	5400000	USD
CY2015Q2	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	40800000	USD
CY2014Q4	gale	Purchase Agreement Term PurchaseAgreementTerm	P36M
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	27020000	USD
CY2014Q4	gale	Sales And Distributions Rights SalesAndDistributionsRights	14533000	USD
CY2015Q2	gale	Sales And Distributions Rights SalesAndDistributionsRights	13946000	USD
CY2014Q4	gale	Sales And Distributions Rights Zuplenz SalesAndDistributionsRightsZuplenz	8101000	USD
CY2015Q2	gale	Sales And Distributions Rights Zuplenz SalesAndDistributionsRightsZuplenz	8101000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	16000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	89000	USD
CY2015Q1	gale	Stock Issued During Period Shares Overallotment Option StockIssuedDuringPeriodSharesOverallotmentOption	1826923	shares
CY2015Q2	gale	Stock Issued During Period Shares Overallotment Option StockIssuedDuringPeriodSharesOverallotmentOption	3653846	shares
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	182186	shares
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2271000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2318000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	643000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1272000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	160000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	160000	USD
CY2014Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	98000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	189000	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	442000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	588000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19408000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33719000	shares
CY2014Q4	us-gaap	Assets Assets	80488000	USD
CY2015Q2	us-gaap	Assets Assets	101967000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	29024000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	51122000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47787000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39162000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23650000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45279000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8625000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	21629000	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.47
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.08
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1826923	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8540000	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	22308000	shares
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	44459000	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3653846	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110100701	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	121457118	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109425701	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	121457118	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	347000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	678000	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	468000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	861000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	18114000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	32136000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	14651000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	28527000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0845
CY2013Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P30M
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2014Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	87000	USD
CY2015Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	78000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	461000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	816000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2198000	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1974000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	44000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	200000	USD
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	162000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7Y
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7534
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0120
CY2014Q4	us-gaap	Goodwill Goodwill	6069000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	6069000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-624000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	47000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1531000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-21000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3122000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2246000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	47000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	771000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	339000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-290000	USD
CY2014Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-314000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-628000	USD
CY2015Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-207000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-449000	USD
	us-gaap	Interest Paid InterestPaid	423000	USD
	us-gaap	Interest Paid InterestPaid	312000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	57000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	655000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	1426000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	455000	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1264000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	43429000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	52602000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80488000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101967000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27233000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	38114000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3910000	USD
CY2015Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	4079000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4492000	USD
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2546000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14739000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45613000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2344000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-569000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21020000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23415000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-19941000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	4504000	USD
CY2013Q4	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22477000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-15660000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26197000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15783000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27632000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11269000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22395000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-491000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-656000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	83000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-238000	USD
CY2014Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-4158000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	5155000	USD
CY2015Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-4391000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-3802000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2315000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2680000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2399000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	10000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	2000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47416000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	38000000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	91000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	110000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4070000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	555000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	532000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1914000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8069000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14839000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7290000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13200000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000	USD
	us-gaap	Sales Discounts Services SalesDiscountsServices	0	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2331000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	3382000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	6132000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9600000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16430000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6451000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13878000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3136000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1272000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7853
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7332
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.742
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0206
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0169
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6169000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	860000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3682000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.09
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.14
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	820000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	892000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8590000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11411000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.25
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.82
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	749000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.85
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.48
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.73
CY2015Q1	us-gaap	Share Price SharePrice	1.56
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M4D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M2D
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	24358974	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1000	shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-10296000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	110000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	47416000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	37059000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	49365000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37059000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	49365000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118083988	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	117154099	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	161383398	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	148647581	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:inherit;font-size:10pt;"> — Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the company’s cash equivalents were invested in money market mutual funds. The company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> — The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001390478-15-000037-index-headers.html	Edgar Link	pending
0001390478-15-000037-index.html	Edgar Link	pending
0001390478-15-000037.txt	Edgar Link	pending
0001390478-15-000037-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20150630.xml	Edgar Link	completed
gale-20150630.xsd	Edgar Link	pending
gale-20150630x10q.htm	Edgar Link	pending
gale-20150630xex101.htm	Edgar Link	pending
gale-20150630xex102.htm	Edgar Link	pending
gale-20150630xex104.htm	Edgar Link	pending
gale-20150630xex105.htm	Edgar Link	pending
gale-20150630xex31.htm	Edgar Link	pending
gale-20150630xex311.htm	Edgar Link	pending
gale-20150630xex312.htm	Edgar Link	pending
gale-20150630xex321.htm	Edgar Link	pending
gale-20150630xex41.htm	Edgar Link	pending
gale-20150630_cal.xml	Edgar Link	unprocessable
gale-20150630_def.xml	Edgar Link	unprocessable
gale-20150630_lab.xml	Edgar Link	unprocessable
gale-20150630_pre.xml	Edgar Link	unprocessable
gale-201506_chartx46249.jpg	Edgar Link	pending
gale-201506_chartx47273.jpg	Edgar Link	pending
pipeline4302015a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2015 Q2 Form 10-Q Financial Statement

#000139047815000037 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2015 Q2 Form 10-Q Financial Statement

#000139047815000037 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls